US 10,703,733 B2Granted

MCL-1 inhibitors

AssigneeGilead Sciences, Inc.

InventorsHang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Claims27

Dependent claims

A compound, or a pharmaceutically acceptable salt thereof, selected from:

Dependencies are inferred from the claim text.

Facts

Application: 16/410,457Filed 13 May 2019 · us provisional application
Priority: 14 May 2018
Published: US 2019/0352271 A121 Nov 2019
Granted: 7 Jul 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07D 267/20
Condensed with two six-membered rings: [b, f]-condensed
C07D 513/08
In which the condensed system contains two hetero rings: bridged systems
A61K 31/553
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine,…
A61P 35/00
Antineoplastic agents

Family

Application62/671,306Us provisional application · filed 14 May 2018
Application62/749,918Us provisional application · filed 24 Oct 2018
US 2019/0352271 A1Pre-grant publication · published 21 Nov 2019
US 10,703,733 B2This patent

From the US filing history. Foreign family members aren’t listed.